Modeling huntington disease in Drosophila: Insights into axonal transport defects and modifiers of toxicity

Fly

Volumn 7, Issue 4, 2013, Pages

  Krench, Megan ^a   Littleton, J Troy ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Aggregates; Axonal transport; Drosophila; Huntington disease; Polyglutamine

Indexed keywords

DROSOPHILA MELANOGASTER; MAMMALIA;

EID: 84887472610     PISSN: 19336934     EISSN: 19336942     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986; 315:1267-76; PMID:2877396
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-83; PMID:8458085; http://dx.doi. org/10.1016/0092-8674(93)90585-E
3. Walker FO. Huntington's disease. Lancet 2007; 369:218-28; PMID:17240289; http://dx.doi. org/10.1016/S0140-6736(07)60111-1
4. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007; 30:575-621; PMID:17417937; http://dx.doi.org/10.1146/ annurev.neuro.29.051605.113042
5. Kratter IH, Finkbeiner S. PolyQ disease: too many Qs, too much function? Neuron 2010; 67:897-9; PMID:20869586; http://dx.doi.org/10.1016/j. neuron.2010.09.012
6. Li Z, Karlovich CA, Fish MP, Scott MP, Myers RM. A putative Drosophila homolog of the Huntington's disease gene. Hum Mol Genet 1999; 8:1807-15; PMID:10441347; http://dx.doi.org/10.1093/ hmg/8.9.1807
7. Li W, Serpell LC, Carter WJ, Rubinsztein DC, Huntington JA. Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein. J Biol Chem 2006; 281:15916-22; PMID:16595690; http://dx.doi.org/10.1074/jbc. M511007200
8. Collins CA, DiAntonio A. Synaptic development: insights from Drosophila. Curr Opin Neurobiol 2007; 17:35-42; PMID:17229568; http://dx.doi. org/10.1016/j.conb.2007.01.001
9. Robertson AL, Bottomley SP. Towards the treatment of polyglutamine diseases: the modulatory role of protein context. Curr Med Chem 2010; 17:3058-68; PMID:20629626; http://dx.doi. org/10.2174/092986710791959800
10. Lee WC, Yoshihara M, Littleton JT. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A 2004; 101:3224-9; PMID:14978262; http://dx.doi. org/10.1073/pnas.0400243101
11. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, Thompson LM. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000; 9:13-25; PMID:10587574; http://dx.doi. org/10.1093/hmg/9.1.13
12. Harjes P, Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003; 28:425-33; PMID:12932731; http://dx.doi.org/10.1016/ S0968-0004(03)00168-3
13. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125:1179-91; PMID:16777606; http://dx.doi.org/10.1016/j.cell.2006.04.026
14. Atwal RS, Desmond CR, Caron N, Maiuri T, Xia J, Sipione S, Truant R. Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol 2011; 7:453-60; PMID:21623356; http://dx.doi. org/10.1038/nchembio.582
15. Havel LS, Wang CE, Wade B, Huang B, Li S, Li XJ. Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet 2011; 20:1424-37; PMID:21245084; http://dx.doi.org/10.1093/hmg/ ddr023
16. Jeong H, Then F, Melia TJ Jr., Mazzulli JR, Cui L, Savas JN, Voisine C, Paganetti P, Tanese N, Hart AC, et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009; 137:60-72; PMID:19345187; http://dx.doi.org/10.1016/j. cell.2009.03.018
17. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 2009; 40:121-7; PMID:18992820; http://dx.doi.org/10.1016/j. mcn.2008.09.007
18. Romero E, Cha GH, Verstreken P, Ly CV, Hughes RE, Bellen HJ, Botas J. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 2008; 57:27-40; PMID:18184562; http://dx.doi.org/10.1016/j.neuron.2007.11.025
19. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A 2005; 102:11402-7; PMID:16076956; http://dx.doi. org/10.1073/pnas.0503634102
20. Gu X, Li C, Wei W, Lo V, Gong S, Li SH, Iwasato T, Itohara S, Li XJ, Mody I, et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005; 46:433-44; PMID:15882643; http://dx.doi.org/10.1016/j. neuron.2005.03.025
21. Lajoie P, Snapp EL. Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS One 2010; 5:e15245; PMID:21209946; http://dx.doi. org/10.1371/journal.pone.0015245
22. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431:805-10; PMID:15483602; http:// dx.doi.org/10.1038/nature02998
23. Carmichael J, Chatellier J, Woolfson A, Milstein C, Fersht AR, Rubinsztein DC. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc Natl Acad Sci U S A 2000; 97:9701-5; PMID:10920207; http://dx.doi.org/10.1073/ pnas.170280697
24. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999; 23:425-8; PMID:10581028; http://dx.doi. org/10.1038/70532
25. Vacher C, Garcia-Oroz L, Rubinsztein DC. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet 2005; 14:3425-33; PMID:16204350; http://dx.doi.org/10.1093/hmg/ddi372
26. Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, Rubinsztein DC. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A 2000; 97:2898-903; PMID:10717003; http:// dx.doi.org/10.1073/pnas.97.6.2898
27. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101:57-66; PMID:10778856; http://dx.doi.org/10.1016/ S0092-8674(00)80623-6
28. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A 2005; 102:892-7; PMID:15642944; http://dx.doi.org/10.1073/ pnas.0408936102
29. Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A 2007; 104:16685-9; PMID:17925440; http://dx.doi.org/10.1073/ pnas.0707842104
30. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B, Sintasath L, Bonini NM, Goldstein LS. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003; 40:25-40; PMID:14527431; http://dx.doi.org/10.1016/ S0896-6273(03)00594-4
31. Sinadinos C, Burbidge-King T, Soh D, Thompson LM, Marsh JL, Wyttenbach A, Mudher AK. Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons. Neurobiol Dis 2009; 34:389-95; PMID:19268537; http://dx.doi.org/10.1016/j.nbd.2009.02.012
32. Morton AJ, Lagan MA, Skepper JN, Dunnett SB. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J Neurocytol 2000; 29:679-702; PMID:11353291; http://dx.doi. org/10.1023/A:1010887421592
33. Wade A, Jacobs P, Morton AJ. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation. Brain Res 2008; 1188:61-8; PMID:18062944; http://dx.doi. org/10.1016/j.brainres.2007.06.059
34. Li H, Li SH, Yu ZX, Shelbourne P, Li XJ. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci 2001; 21:8473-81; PMID:11606636
35. Trushina E, Dyer RB, Badger JD 2, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 2004; 24:8195-209; PMID:15340079; http://dx.doi.org/10.1128/ MCB.24.18.8195-8209.2004
36. Weiss KR, Kimura Y, Lee WC, Littleton JT. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Genetics 2012; 190:581-600; PMID:22095086; http://dx.doi.org/10.1534/genetics.111.133710
37. Schulte J, Sepp KJ, Wu C, Hong P, Littleton JT. High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model. PLoS One 2011; 6:e23841; PMID:21909362; http://dx.doi.org/10.1371/journal.pone.0023841